Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ColActive is an advanced wound care dressing developed by Covalon Technologies. It is a medical device composed of a patented blend of fish-derived collagen, sodium alginate, carboxymethyl cellulose (CMC), and ethylenediaminetetraacetic acid (EDTA). When applied to a wound, the dressing reacts with exudate to form a soft gel, creating a moist environment conducive to granulation and epithelialization. The EDTA component acts by chelating zinc to inhibit matrix metalloproteinases (MMPs), which are often elevated in chronic wounds and can stall healing. The "Plus Ag" version includes silver chloride to provide antimicrobial protection. It is indicated for the management of full- and partial-thickness wounds, including diabetic foot ulcers, pressure ulcers, venous ulcers, and second-degree burns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ColActive.